Hypothesis
Spironolactone, which improves outcomes in heart failure with reduced ejection fraction, would do the same in heart failure with preserved ejection fraction.
What failed
In 3,445 patients with ejection fraction of 45% or more over a mean 3.3 years, the primary composite (cardiovascular death, aborted cardiac arrest or heart-failure hospitalization) occurred in 18.6% vs 20.4% on placebo (HR 0.89, P=0.14). Hyperkalemia doubled (18.7% vs 9.1%).
Broken assumption
Mineralocorticoid-receptor blockade helps heart failure with preserved ejection fraction the way it helps reduced ejection fraction.
Why
A benefit established in reduced ejection fraction did not carry over to preserved ejection fraction on the primary endpoint; only heart-failure hospitalization, one component, fell significantly (12.0% vs 14.2%).
From the published paper: Pitt B, Pfeffer MA, Assmann SF, et al. (TOPCAT). N Engl J Med, 2014. NCT00094302 ↗